AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Acurx Pharmaceuticals Inc... (ACXP)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.76

-0.08 (-9.52%)

At close: Jan 28, 2025, 3:59 PM

0.79

3.21%

After-hours Jan 28, 2025, 06:04 PM EST

undefined% (undefined)

Bid	0.75
Market Cap	14.87M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.09
PE Ratio (ttm)	-0.7
Forward PE	n/a
Analyst	Buy

Ask	0.8
Volume	143,294
Avg. Volume (20D)	277,713
Open	0.85
Previous Close	0.84
Day's Range	0.76 - 0.85
52-Week Range	0.68 - 3.77
Beta	undefined

About ACXP

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bac...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 25, 2021

Employees 4

Stock Exchange NASDAQ

Ticker Symbol ACXP

Website https://www.acurxpharma.com

Analyst Forecast

According to 1 analyst ratings, the average rating for ACXP stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 1472.74% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

3 weeks ago

-26.01%

Acurx Pharmaceuticals shares are trading lower aft... Unlock content with Pro Subscription

3 weeks ago

+22.49%

Acurx Pharmaceuticals shares are trading higher after the company announced the European Medical Agency (EMA) granted positive regulatory guidance for its Ibezapolstat Phase 3 program for C. Difficile Infection.

News

2 months ago · zacks.com

Here's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock Now

Acurx Pharmaceuticals (ACXP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreemen...

2 months ago · cnbc.com

Acurx Pharmaceuticals to add up to $1 million in bitcoin for treasury reserve, following MicroStrategy's playbook

The board of Acurx Pharmaceuticals has approved the purchase of up to $1 million in bitcoin to hold as a treasury reserve asset.

2 months ago · seekingalpha.com

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Robert Shawah - Co-Founder & CFO David Luci - Co-Founder, President, CEO, ...